A Study of CAR-T Cells Targeting Both BCMA and GPRC5D in Treatment of Relapsed or Refractory Multiple Myeloma

An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D Dual Target CAR-T Cells Therapy in Patients With Relapsed or Refractory Multiple Myeloma

Status

UNKNOWN

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05325801

Enrollment

Registered

2022-04-13

Start date

2022-04-30

Completion date

2025-03-31

Last updated

2022-04-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Myeloma

Brief summary

An Open-Label, Dose Finding Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of BMCA and GPRC5D dual target CAR-T cells therapy in Patients with relapsed or refractory multiple myeloma

Interventions

BIOLOGICALBMCA and GPRC5D dual target CAR-T cells(OriC321)

Patients will receive lymphodepleting chemotherapy followed by a single infusion of OriC321

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Inclusion criteria

* Signed and dated, written informed consent prior to any study specific procedures; * Estimated life expectancy of minimum of 12 weeks; * ECOG 0-2; * Diagnosed as multiple myeloma according to the IMWG criteria; * Evidence of cell membrane GPRC5D and/or BCMA expression, as determined by a validated immunohistochemistry (IHC) or flow cytometry of tumor tissue; Subjects should have measurable disease. At least meet one of the following criteria: 1. If IgG type MM, serum M protein ≥10g/L; if IgA, IgD, IgE or IgM type MM, serum M protein ≥5g/L; 2. urine M protein level ≥0.2g(200mg/24h); 3. light chain type MM, serum free light chain (sFLC) ≥ 100mg / L and K/ λ FLC ratio is abnormal; 4. there are extramedullary lesions; * Subjects have had at least 3 prior lines of therapy including chemotherapy based on proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs); * Adequate organ functions

Exclusion criteria

* Active smoldering multiple myeloma; * Active plasma cell leukemia; * With organ amyloidosis; * Central nervous system (CNS) involvement; * Pregnant or breastfeeding; * Hepatitis B virus (HBV) surface antigen (HBsAg) or hepatitis B core antibody-positive and detectable HBV DNA in peripheral blood; Hepatitis C virus (HCV) antibody and hepatitis C virus RNA in peripheral blood; Human immunodeficiency virus (HIV) antibody * Uncontrolled Hypertension hypertension defined as a blood pressure (BP) ≥150/95 mmHg; Symptomatic heart failure per New York Heart Association Classification Class II, III or IV), Mean resting corrected QT interval corrected by Fridericia's formula (QTcF) \> 470 msec (female), 450 msec (male) obtained from ECG; Baseline left ventricular ejection fraction (LVEF) below institution's lower limit of normal (LLN) or \<50%; * Have a history of another primary malignancy within 5 years prior to starting study treatment. Exceptions here are as follows: the disease under study; adequately treated basal or squamous cell carcinoma of the skin; cancer of the cervix in situ.

Design outcomes

Primary

Measure	Time frame
Incidence, severity AEs/SAEs	2 years after CAR-T cell infusion

Secondary

Measure	Time frame
Concentration of CAR-T cells	2 years after CAR-T cell infusion
Objective response rate (ORR)	2 years after CAR-T cell infusion
Progression-free survival (PFS)	2 years after CAR-T cell infusion
Duration of response (DOR)	2 years after CAR-T cell infusion
Overall survival (OS)	2 years after CAR-T cell infusion
Percentage of Patients With Negative Minimal Residual Disease (MRD)	2 years after CAR-T cell infusion

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026